Breast Cancer Tops List of Malpractice Claims

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

WASHINGTON--Breast cancer leads the list of diseases for which malpractice claims have been filed in the last decade, according to a study from the Physician Insurers Association of America. Of 117,000 claims filed since 1985, about 2,500 involved breast cancer.

WASHINGTON--Breast cancer leads the list of diseases for whichmalpractice claims have been filed in the last decade, accordingto a study from the Physician Insurers Association of America.Of 117,000 claims filed since 1985, about 2,500 involved breastcancer.

The association stressed that this number is small compared withthe estimated 1.5 million women who received a breast cancer diagnosisduring that period.

In an analysis of 487 delay in diagnosis claims, the average delaywas 14 months; 91% of these patients were under age 50. Although60% of these women found a lump by self-examination, in 35% ofcases, the "physical findings failed to impress the physician,"the study said, and this was the most common reason for delay.The second leading cause was failure to follow up on physicalexams and inconclusive mammograms.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content